Impact of Upadacitinib Versus Abatacept on Individual Disease Outcomes in Patients With Rheumatoid Arthritis and Inadequate Responses to Biologic DMARDs

Category Primary study
JournalSwiss Medical Weekly
Year 2022
This article has no abstract
Epistemonikos ID: 0199797dda77df24aa9828a3327d51a75fcaa4c9
First added on: Feb 15, 2025